An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model"
- PMID: 23363553
- PMCID: PMC3568412
- DOI: 10.1186/1471-2334-13-54
An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model"
Abstract
Background: To update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011.
Methods: The rotavirus burden of disease and the indirect protection of older children and young adults (herd protection) were updated.
Results: When updated data was used, routine infant rotavirus vaccination in the Netherlands would potentially become an even more cost-effective strategy than previously estimated with the incremental cost per QALY at only €3,000-4,000. Break-even total vaccination costs were indicated at €92-122, depending on the applied threshold.
Conclusions: We concluded that the results on potentially favourable cost-effectiveness in the previous study remained valid, however, the new data suggested that previous results might represent an underestimation of the economic attractiveness of rotavirus vaccination.
References
-
- Bruijning-Verhagen P, de Waal W, Winkel L, Felderhof M, van Houten M, Thijsen S, Rotavirus related hospitalizations: Incidence and contribution to seasonal peaks in pediatric hospital admissions. Thessaloniki, Greece: Poster at ESPID-conference 2012; 2012.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
